<DOC>
	<DOCNO>NCT00000827</DOCNO>
	<brief_summary>To evaluate safety , tolerance , pharmacokinetics , antiviral activity human anti-HIV immune serum globulin ( HIVIG ) three dosage level HIV-infected child . Passive antibody therapy use limited success treat advanced HIV disease adult . HIVIG manufacture HIV antibody-rich plasma take asymptomatic donor . It hypothesize HIVIG decrease viral burden moderately advance HIV-positive child .</brief_summary>
	<brief_title>A Phase I/II Study Hyperimmune IVIG Slowing Progression Disease HIV-Infected Children</brief_title>
	<detailed_description>Passive antibody therapy use limited success treat advanced HIV disease adult . HIVIG manufacture HIV antibody-rich plasma take asymptomatic donor . It hypothesize HIVIG decrease viral burden moderately advance HIV-positive child . Children randomize receive HIVIG every 4 week 6 month one three dose level , follow 3 month final infusion .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immune Sera</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Required : PCP prophylaxis accord CDC guideline . Allowed : Varicellazoster immunoglobulin . Hepatitis B immunoglobulin . Prophylactic therapy involve immunoglobulin . Patients must : HIV infection . CD4 count &gt; 200 cells/mm3 ( age 25 year ) &gt; 100 cells/mm3 ( age &gt; 5 year ) . Antiretroviral therapy least 6 month , change regimen least 3 month prior study entry . Plasma ICD p24 &gt; = 70 pg/ml stable increase prior study entry . Life expectancy least 6 month . Prior Medication : Required : Antiretroviral therapy least 6 month , stable dose least 3 month . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Severe diarrhea , nephrotic syndrome , proteinlosing state require large dos IVIG . Any condition require dose IVIG ( e.g. , ITP , hypogammaglobulinemia ) . Acute illness temperature &gt; = 100 F and/or IV antibiotic . Grade 3 bad clinical toxicity . Unable tolerate IV infusion minimum rate 0.02 ml/kg/min . Concomitant participation experimental antiretroviral HIV vaccine trial . Concurrent Medication : Excluded : IVIG . Chemotherapy active malignancy . MMR rubella vaccination . Intramuscular immunoglobulin . Patients follow prior condition exclude : History severe reaction IVIG . Prior Medication : Excluded : IVIG within past 60 day . Chemotherapy active malignancy within past year . MMR rubella vaccination within past 6 month . Intramuscular immunoglobulin within past 60 day . Ongoing drug alcohol abuse .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Immunoglobulins , Intravenous</keyword>
	<keyword>Immunization , Passive</keyword>
</DOC>